Johnson & Johnson (JNJ) Investor update summary

Strategic vision and market opportunity

• OTTAVA is positioned as a category-defining, table-integrated robotic surgery system, aiming to expand the U.S. market and drive global adoption, with fewer than 8% of relevant procedures worldwide currently performed robotically.

• The initial launch targets early adopters and high-volume centers, with plans for rapid expansion of indications and entry into Europe and Japan.

• Commercial strategy emphasizes value-based pricing, flexible commercial models, and leveraging existing relationships with hospitals and surgeons.

• The program is expected to be financially material by the end of the decade, with more detailed guidance to be provided at the December Enterprise Business Review.

Product differentiation and innovation

• OTTAVA features a novel architecture with integrated surgical arms and table, reducing OR footprint by 30%-50% and enabling use in smaller or previously unsuitable rooms.

• Twin Motion technology allows synchronized movement of table and arms, eliminating the need to stop or reposition during surgery.

• Automation is built in from day one, with automated procedure poses and motorized arms streamlining setup and teardown.

• The open digital ecosystem, Polyphonic, supports data-driven insights, learning, and secure data capture for continuous improvement.

Clinical validation and user feedback

• In the FORTE trial, OTTAVA achieved 100% procedural completion without conversion, with 100% of surveyed staff agreeing it unlocks space and 95% citing efficiency gains.

• Surgeons and staff reported improved workflow, communication, and the ability to use robotic systems in previously inaccessible ORs.

• Early feedback led to rapid product iteration, such as customized arm positioning based on clinical trial input.

• The learning curve for surgeons is described as shallow, with professional education supporting rapid adaptation.